IGF::OT::IGF CORE INFRASTRUCUTE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) STUDY PERIOD OF PERFORMANCE 05/01/2015-04/30/2016

SEER计划于1972年启动，以响应国家癌症计划的要求，评估美国癌症负担的大小，并确定与癌症风险和/或患者生存相关的因素。SEER计划的目标包括： 1.定期收集和报告癌症发病率的估计数字，特别是在以下关键癌症部位：乳腺癌、肺癌、结直肠癌、前列腺癌、胰腺癌和膀胱癌。 2.监测每年的癌症发病率趋势，以确定在由地理、人口和社会特征定义的人口亚群中发生的特定癌症的不寻常变化。 3.提供有关确诊时疾病范围随时间的变化、治疗趋势和癌症患者生存变化的持续信息。 4.确定可能发生的医源性癌症，即由癌症治疗引起的癌症。 5.作为国家癌症研究所的研究资源，开展关于当前癌症控制问题以及与SEER计划运行有关的问题的研究。

The SEER Program was initiated in 1972 in response to requirements of the National Cancer Program for assessing the magnitude of the cancer burden in the United States, and for identifying factors related to cancer risk and/or patient survival. The SEER Program has among its objectives: 1. To assemble and report, on a periodic basis, estimates of cancer incidence, especially among the following key cancer sites: breast cancer, lung cancer, colorectal cancer, prostate cancer, pancreatic cancer, and urinary bladder cancer. 2. To monitor annual cancer incidence trends to identify unusual changes in specific forms of cancer occurring in population subgroups defined by geographic, demographic, and social characteristics. 3. To provide continuing information on changes over time in extent of disease at diagnosis, trends in therapy, and changes in cancer patient survival. 4. To identify the occurrence of possible iatrogenic cancers, i.e., cancers that are caused by cancer therapy. 5. To serve as a research resource to the National Cancer Institute, and conduct studies dealing with current cancer control issues as well as problems related to the operation of the SEER Program.